Charcot-Marie-Tooth (CMT) disease is a common neurogenetic disorder and its heterogeneity is a challenge for genetic diagnostics. The genetic diagnostic procedures for a CMT patient can be explored according to the electrophysiological criteria: very slow motor nerve conduction velocity (MNCV) (<15 m/s), slow MNCV (15-25 m/s), intermediate MNCV (25-45 m/s), and normal MNCV (>45 m/s). Based on the inheritance pattern, intermediate CMT can be divided into dominant (DI-CMT) and recessive types (RI-CMT). GJB1 is currently considered to be associated with X-linked DI-CMT, and MPZ, INF2, DNM2, YARS, GNB4, NEFL, and MFN2 are associated with autosomal DI-CMT. Moreover, GDAP1, KARS, and PLEKHG5 are associated with RI-CMT. Identifi cation of these genes is not only important for patients and families but also provides new information about pathogenesis. It is hoped that this review will lead to a better understanding of intermediate CMT and provide a detailed diagnostic procedure for intermediate CMT.
Introduction
Charcot-Marie-Tooth disease (CMT), also known as hereditary motor and sensory neuropathy, is one of the most common inherited neurologic disorders, with an estimated prevalence of 17 to 40 per 10,000 [1] . Currently, ~53 loci or 49 different genes are associated with CMT (http://neuromuscular.wustl.edu/time/hmsn.html). CMT can be transmitted through autosomal dominant, autosomal recessive, or X-linked inheritance [2] . Clinically, it is characterized by progressive muscle weakness and atrophy of the distal extremities, distal sensory loss, reduced or absent deep tendon reflexes, and foot deformities [3] .
Uniformly slow motor nerve conduction velocity in the or in axonal CMT with normal MNCVs [4] . Therefore, the concept of intermediate CMT with mMNCVs of 25 to 45 m/s appeared in the 1970s and has recently become more popular due to the importance of direct genetic diagnosis [5] .
Previously, autosomal dominant intermediate (DI) CMT
was only classified into three types: DI-CMTA, DI-CMTB, and DI-CMTC [6] [7] [8] . Currently, GJB1 is considered to be associated with X-linked DI-CMT, and MPZ, NEFL, GNB4,
INF2
, and MFN2 are associated with autosomal DI-CMT.
In addition, GDAP1, KARS, and PLEKHG5 are associated with autosomal recessive intermediate CMT (RI-CMT).
The information on these genes is shown in Table 1 and statistics of their mutations and phenotypes are listed in Table 2 . [9] , and two apposed hemichannels form a functional channel which provides a contiguous pathway between adjacent cells or cellular compartments. The channel diameter is too small to allow the transfer of nucleic acids or proteins, but is large enough to allow the diffusion of ions and other small particles (<1000 Da) [10] . Many of the connexin channels are located in the cell membrane, where they are called gap junctions. In GJB1 mutants, the formation of functional gap junctions is disrupted or abnormal gap junctions are formed, and this is considered to be the main pathological mechanism of GJB1 mutation [11] . Affected males with the CMT1X phenotype have moderate to severe symptoms, whereas heterozygous females are usually less affected with mild symptoms. The mMNCV typically ranges from 30 to 40 m/s in affected males with GJB1 mutation and 30-50 m/s in affected females with the CMT1X phenotype, which is faster than in patients with the demyelinating form and slower than in patients with the axonal form of CMT [11] [12] [13] .
In 2014, we discussed the clinical and electrophysiological features in a cohort of 59 Chinese CMT1X patients. We found that the mean MNCV of male patients is 34.5 ± 6.3 m/s and that of female patients 43.5 ± 7.2 m/s [14] . As intermediate CMT with mMNCVs between 25 and 45 m/s is often found in CMT1X patients [15] , GJB1 mutation analysis is the fi rst step to genetically diagnose a CMT patient with an intermediate MNCV if there is no sign of male-to-male transmission.
MPZ and DI-CMTD Phenotype
MPZ is located on chromosome 1q23.3 and is 7 kb in size [16, 17] . It has six exons encoding myelin protein zero (P 0 ). The mature protein contains 219 amino-acids and has a cytoplasmic domain, a single transmembrane domain,
and an extracellular domain [17, 18] . The majority of MPZ mutations are located on exon 2 or 3 which corresponds to the immunoglobulin-like extracellular domain, whereas mutations in the intracellular and transmembrane domains are less frequent [19] . P 0 is the major protein constituent of peripheral myelin, comprising ~50% of all peripheral nervous myelin proteins [20] . P 0 is essential for the commencement of myelination and the maintenance of myelin compaction [21] . The compaction of myelin lamellae relies on homotypic interactions between the extracellular domains of P 0 [22] . Therefore, mutant P 0 can not only directly influence the formation and compaction of the myelin sheath, but also indirectly result in axonal degeneration.
So far, >160 MPZ mutations have been reported, giving rise to demyelinating, axonal, and intermediate CMT forms
with a wide range of severity [23] . Approximately 30% of MPZ resulting in premature termination of protein translation [23] .
Electrophysiological and pathological studies in this English
CMT family revealed demyelination and axonal loss with m MNCVs in the intermediate range (38-43 m/s) [23] . In 2013,
we presented four CMT families and one CMT patient with MPZ mutations. Three were classifi ed as intermediate CMT with mMNCVs ranging from 32.8 to 45 m/s [26] . It has been suggested that MPZ is the second most frequent gene resulting in intermediate CMT (Table 2) . Therefore, MPZ mutation should be tested in CMT families with intermediate mMNCVs (25-45 m/s), especially when GJB1 mutations are negative or there is male-to-male transmission [24, 27] .
INF2 and DI-CMTE Phenotype
INF2 is located on chromosome 14q32.33, and encodes inverted formin-2 (INF-2), a member of the diaphanousrelated formin family, which is involved in remodeling the microtubule cytoskeleton and actin [28] . INF2 interacts with Rho-GTPase CDC42, lymphocyte protein, and myelin, which are implicated in essential steps of the commencement of myelination and maintenance [29] [30] [31] .
Like other diaphanous-related formins, INF2 contains an N-terminal diaphanous-inhibitory domain, two forminhomology domains, and a C-terminal diaphanousautoregulatory domain [32] . Immunohistochemical analysis has revealed that INF2 is expressed in the cytoplasm of Schwann cells and kidney podocytes, so it is involved in diseases affecting both the peripheral nervous system and the renal glomerulus [31] . females and 2 males), and found chronic demyelination and remyelination associated with progressive axonal loss [37] . In the same year, Park et al. described a novel INF2 mutation (p.L132P) in a family with intermediate CMT and FSGS in two affected members; this was the fi rst reported case from Korea [35] . The clinical features of DI-CMTE include age at onset 5-28 years, proteinuria, mild to severe weakness, pes cavus, reduced tendon refl exes, sensory loss in 50% of patients, sensorineural hearing loss in 30% of patients, cramps, and mMNCV 23-45 m/s.
DNM2 and DI-CMTB Phenotype
DNM2 is located on 19p13.2, and encodes dynamin-2 protein (DNM2) [7] . DNM2 possesses five characteristic domains: a highly conserved N-terminal GTPase domain, a middle domain that binds to γ-tubulin, a pleckstrinhomology domain that interacts with phosphoinositides, a GTPase effector domain, and a proline/arginine-rich domain at the C-terminus [38] [39] [40] . DNM2 belongs to a family of large GPases that regulate membrane traffi cking, actinbased dynamics, and the membrane fusion and fission of vesicles, peroxisomes, and mitochondria [41] . DNM2
mutations cause not only DI-CM TB, but also the CMT2M
phenotype. The majority of DNM2 mutations are located in the pleckstrin-homology domain, and other mutations with similar phenotypes have been reported in the Pro/ Arg-rich domain and the middle domain [42] . patients are wheel-chair bound [42] . Some patients also have combined nuclear and cortical cataracts that occur in early life. In some families with DNM2 mutation, the patients have also been segregated with neutropenia, ptosis, and ophthalmoparesis [42, 43] .
YARS and DI-CMTC Phenotype
YARS encodes tyrosyl-tRNA synthetase (TyrRS) and is located on chromosome 1p35.1 [44] . Aminoacyl-tRNA synthetases (ARSs) charge amino-acids onto their homologous tRNAs during protein translation. First, studies suggested that insufficient enzyme activity in protein synthesis is the mechanism of ARS-related CMT. Second, the mutant proteins were thought to lead to ubiquitinpositive misfolded protein aggregates and the formation of toxins [45] . Mutations in glycyl-, tyrosyl-, and alanyl-tRNA synthetases have been associated with CMT [45] . TyrRS is expressed ubiquitously and is an essential enzyme for protein biosynthesis. It catalyzes the aminoacylation of tRNA Tyr with tyrosine in two steps: tyrosine activation by ATP to form tyrosyl-adenylate, and transfer of the activated form to cognate tRNA Tyr [46] . The intermediate CMT caused
by YARS mutations is defi ned as the DI-CMTC phenotype.
Some studies have shown that the pathogenesis of this phenotype is not due to haploinsufficiency of aminoacylation activity, but most probably to an increased functional alteration of the mutant TyrRS [47] . In 2006,
Jordanova et al. reported two mutations in YARS,
p.Gly41Arg and p.Glu196Lys, in two unrelated DI-CMTC families from North America and Bulgaria, and a 12-bp inframe deletion (153-156delVKQV) in an affected individual from Belgium [6] . In the North American and the Bulgarian families with YARS mutations, the clinical features were age at onset between 10 and 60 years, intermediate MNCV ranging from 25 to 58 m/s, slow progression, and moderate severity [44] .
GNB4 and DI-CMTF Phenotype
GNB4 is located on chromosome 3q26.33 and encodes guanine-nucleotide-binding protein subunit beta-4 (Gβ 4 ).
Guanine-nucleotide-binding proteins are heterotrimeric, composed of α, β, and γ subunits. They can act in concert with different G-protein-coupled receptors to transmit extracellular signals into cells. And these receptors can be activated by many different signaling factors, such as hormones, neurotransmitters, and cytokines [48] . Gβ 4 is colocalized with neurofilament heavy chain, indicating that it is abundant in Schwann cells and axons in peripheral nerves [49] . In 2013, Yi-Chung Lee et al. reported that GNB4 mutation is a cause of DI-CMT using genomewide linkage and exome sequencing in a Chinese family (six affected individuals, five unaffected individuals, and two married-in spouses). They revealed a heterozygous mutation, c.158G>A (p.Gly53Asp), in GNB4 in two affected first cousins [49] . The disease status of this family included age of onset ranging from 10 to 45 years, clinical severity from asymptomatic to wheelchair-bound (only one patient needed a wheelchair), mMNCVs from 16.5 to 45.7 m/s, and men tending to be more severely affected [49] . Subsequently, another GNB4 de novo mutation, c.265A>G (p.Lys89Glu), was identifi ed in a Chinese CMT patient [49] . The frequency of GNB4 mutations in the CMT population in that study was estimated to be ~0.8% [49] . The intermediate CMT caused by GNB4 mutation is defi ned as a DI-CMTF phenotype.
NEFL and the Associated Phenotype
NEFL is located on chromosome 8p21 [50] and encodes There is a consensus that the radial accumulation of neurofilaments leads to the lateral growth of axons during myelination, and therefore can determine the axon diameter and the conduction velocity of peripheral nerves to some extent [51, 52] . It is supposed that NEFL mutants not only infl uence the normal assembly of neurofi laments, but also cause aggregate formation that prevents transport or other physiological functions of the axon [53] . Moreover, NEFL mutants impede neurofilament assembly and transport in vivo and affect mitochondrial morphology by interfering with mitochondrial dynamics in a cellular model of the CMT2E/1F phenotype [54, 55] . NEFL mutations can result in CMT neuropathies with variable clinical and electrophysiological features. The p.Gln333Pro mutation caused a mild CMT2E phenotype in a Russian family; the p.Pro8Arg mutation led to a classical and more severe CMT phenotype in a Belgian kindred [56] . According to the electrophysiological criteria, most Belgian CMT patients in this study could be diagnosed as CMT1 phenotype, but as a whole the family could be classifi ed into intermediate CMT [57] . Taken together, NEFL mutations can cause CMT1, CMT2, and intermediate CMT.
10q24.1-q25.1 Locus and DI-CMTA Phenotype
Kristien Verhoeven et al. performed a genome-wide search in an Italian family exhibiting autosomal DI-CMT and mapped the locus on chromosome 10q24.1-q25.1 [8] . This [58] . Loss of large myelinated axons and occasional onion bulbs were found in nerve biopsies [59] . So far, the pathogenic gene for DI-CMTA has not been cloned and cases of the DI-CMTA phenotype have rarely been reported.
Genes Associated with Recessive Intermediate

CMT
GDAP1 and RI-CMTA Phenotype
GDAP1 is located on chromosome 8q21.11 and spans ~17 kb of genomic DNA [60] . Its encoded protein, gangliosideinduced differentiation associated-protein 1 (GDAP1), has fi ve domains: two glutathione-S-transferase (GST) domains, an α-helical domain (also called a 4-5 loop), a hydrophobic domain, and a transmembrane domain [61] [62] [63] . This protein is anchored to the outer mitochondrial membrane of neurons and Schwann cells through the transmembrane domain.
GDAP1 plays an important role in mitochondrial dynamics and functioning [64, 65] . Another important function of GDAP1 is due to the GST domains: it regulates glutathione metabolism, sensitivity to apoptosis, and reactive oxygen species levels [66] . GDAP1 mutations are associated with CMT4A, the most frequent recessive demyelinating CMT phenotype, with AR-CMT2K, the recessive axonal CMT phenotype, with CMTRIA, the recessive intermediate CMT with mixed features of demyelinating and axonal forms, and with AD-CMT2K, the rare dominant phenotype [67] [68] [69] [70] . and axonal loss as well as demyelinating changes in the peripheral nerve pathology [71] . In 2006, Kabzinska et al.
found a homozygous mutation (p.Leu239Phe) of GDAP1 in a 39-year-old female with severe intermediate CMT [69] . This intermediate CMT caused by GDAP1 mutation is defined as the RI-CMTA phenotype.
KARS and RI-CMTB Phenotype
KARS is located on chromosome 16q23.1 and spans ~20 kb [72] . It encodes Lysyl-tRNA synthetase, the enzyme responsible for charging tRNA Lys molecules. Importantly, KARS is the only locus in the human genome encoding an enzyme responsible for tRNA Lys charging and it is essential for protein translation in both the cytoplasm and mitochondria [72, 73] . ARSs charge amino-acids onto their cognate tRNAs during protein translation. Three ARS genes (GARS, YARS, and AARS) are associated with the CMT2D, DI-CMTC, and CMT2N phenotypes [6, 74, 75] . [73] . One is a heterozygous mutation (p.Ile302Met) and the other is a compound heterozygous mutation (p.Leu133His;
c.524_525insTT) [73] . The mMNCVs of these patients were mildly slowed, ranging from 30 to 40 m/s. In addition, they had dysmorphic features, developmental delay, and vestibular Schwannoma [73] . This intermediate CMT caused
by KARS mutations is defi ned as the RI-CMTB phenotype.
PLEKHG5 and the RI-CMTC Phenotype
PLEKHG5 is located on chromosome 1p36.31, within a 1.5 Mb interval [76] . Pleckstrin homology domain-containing family G member 5 (PLEKHG5) is predominantly expressed in the peripheral nervous system, and it possesses a Dblhomology -pleckstrin-homology motif, which is the minimal unit for the nucleotide exchange-promoting function of guanine nucleotide exchange factors (GEFs) [77] . Pleckstrinhomology domains also independently play an important role in the allosteric regulation of the RhoGEF domain.
The RhoGEF domain can activate GTPases by stimulating the exchange of GDP and GTP, thereby many signaling mechanisms are initiated that regulate neuronal shape and plasticity, dendrite growth, synapse formation, and neuronal survival [76] . [79] .
Immunohistochemical studies revealed that the patients expressed a low level of PLEKHG5 in the distal sural nerve and in vitro assays suggested that the PLEKHG5 mutants are defective in activating the NF-κB signaling pathway [79] . Norwegian CMT cases and confirmed that MFN2 gene mutation can also cause intermediate CMT [80] . Of these genes, some are also associated with the classical CMT1 [81] . Figure 3 . 
Diagnostic Procedure for Intermediate CMT
Conclusion
